Precision anti-infective technology focused on a microbiome sparing strategy. We target Clostridioides difficile infection (CDI), an antibiotic-associated infectious diarrheal disease, through oral delivery of a targeted Antisense Oligonucleotide.

The Atmospherica process utilizes naturally occurring, photosynthetic, shell-forming micro-algae to sequester CO2 and store it as calcium carbonate, a highly durable mineral that is stable for millions of years. It is a safe and relatively easy process that can be implemented quickly and cost effectively.

Our data-driven platform integrates high-throughput analytics and AI for next-generation drug discovery. We leverage novel insights into the foundational biologic pathways of neurodegenerative diseases to discover, evaluate, and develop disease-modifying therapeutics for Alzheimer’s disease, frontotemporal dementia (FTD) , amyotrophic lateral sclerosis (ALS), and other degenerative diseases of the nervous system.

An EVD or external ventricular drain, is a device used in neurosurgery to relieve intracranial pressure (ICP) resulting from a disturbance in cerebrospinal fluid (CSF) drainage due to tumors, cysts, bleeding, infection, hydrocephalus, and trauma. Existing EVD’s are manually assembled so as to insure appropriate drainage and ICP. Unfortunately, these systems are labor intensive and require full time monitoring by the medical staff.

Using today’s electronic devices and sensors, we have designed an EVD that can provide a completely autonomous solution while providing accuracy and repeatability.

Occult Tethered Cord Syndrome (TCS) is a serious medical condition often detected before birth. If the spinal cord is not free it can result in several other urological problems and can result in a life-long disability.

Senfina offers in vivo whole life drug discovery services for aging and age-related diseases based on a multi-feature high-throughput imaging platform using C. elegans as a model organism.

Safe Lactobacillus-based synthetic biologic as a colonization resistance agent of, and oral vaccine for, Clostridioides difficile infection (CDI).

We offer a novel tool for antibiotic treatment. Our approach targets a broad spectrum of bacteria but eliminates the risk of evolving resistance by targeting a multitude of pathways.